Trial Profile

The phase I study assessing the safety, tolerability, and relative bioavailability of SAGE-217 Capsules

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zuranolone (Primary) ; Zuranolone
Indications Bipolar depression; Dyskinesias; Essential tremor; Insomnia; Major depressive disorder; Parkinson's disease; Postnatal depression; Seizures
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

24 Mar 2023 Results presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
29 Mar 2018 New trial record
24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com